The troublesome toxicity of peripheral neuropathy with thalidomide

Leukemia and Lymphoma

Volumn 47, Issue 11, 2006, Pages 2276-2279

  Mileshkin, Linda ^a,b   Prince, H Miles ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERFERON; MELPHALAN; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; MONITORING; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; SOMNOLENCE; SYSTEMATIC REVIEW;

HUMANS; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; THALIDOMIDE;

EID: 33751094293     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600948303     Document Type: Note

References (25)

1. Cavaletti, G and Bogliun, G and Marzorati, L and Tredici, G and Colombo, N and Parma, G and (1994) Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer Anticancer Res, 14, pp. 1287-1292.
2. Giannini, F and Volpi, N and Rossi, S and Passero, S and Fimiani, M and Cerase, A. (2003) Thalidomide-induced neuropathy: A ganglionopathy? Neurology, 60, pp. 877-878.
3. Chaudhry, V and Cornblath, D and Corse, A and Freimer, M and Simmons-O'Brien, E and Vogelsang, G. (2002) Thalidomide-induced neuropathy Neurology, 59, pp. 1872-1875.
4. Apfel, S and Zochodne, D. (2004) Thalidomide neuropathy: Too much or too long? Neurology, 62, pp. 2158-2159.
5. Umapathi, T and Chaudhry, V. (2005) Toxic neuropathy Curr Opin Neurol, 18, pp. 574-580.
6. Aronson, I and Yu, R and West, D and van den Broek, H and Antel, J. (1984) Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures Arch Dermatol, 120, pp. 1466-1470.
7. Fullerton, P and O'Sullivan, D. (1968) Thalidomide neuropathy: A clinical electrophysiological, and histological follow-up study J Neurol Neurosurg Psychiatry, 31, pp. 543-551.
8. Mileshkin, L and Stark, R and Day, B and Seymour, J and Zeldis, J and Prince, H. (2006) Development of neuropathy in patients with myeloma treated with thalidomide - patterns of occurrence and the role of electrophysiologic monitoring J Clin Oncol, 24, pp. 4507-4514.
9. Offidani, M and Corvatta, L and Marconi, M and Malerba, L and Mele, A and Olivieri, A and (2004) Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy Eur J Haematol, 72, pp. 403-409.
10. Tosi, P and Zamagni, E and Cellini, C and Plasmati, R and Cangini, D and Tacchetti, P and (2005) Neurological toxicity of long-term (>1 year) thalidomide therapy in patients with multiple myeloma Eur J Haematol, 74, pp. 212-216.
11. Glasmacher, A and Hahn, C and Hoffmann, F and Naumann, R and Goldschmidt, H and von Lilienfeld-Toal, M and (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma Br J Haematol, 132, pp. 584-593.
12. Rajkumar, S. (2003) Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease Semin Hematol, 40, pp. 17-22.
13. Rajkumar, S and Blood, E and Vesole, D and Fonseca, R and Greipp, P. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol, 24, pp. 431-436.
14. Barlogie, B and Tricot, G and Anaissie, E and Shaughnessy, J and Rasmussen, E and van Rhee, F and (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma N Engl J Med, 354, pp. 1021-1030.
15. Palumbo, A and Bringhen, S and Caravita, T and Merla, E and Capparella, V and Callea, V and (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial Lancet, 367, pp. 825-831.
16. Molloy, F and Floeter, M and Syed, N and Sandbrink, F and Culcea, E and Steinberg, S and (2001) Thalidomide neuropathy in patients treated for metastatic prostate cancer Muscle Nerve, 24, pp. 1050-1057.
17. Yellen, S and Cella, D and Leslie, W. (1994) Age and clinical decision making in oncology patients J Natl Cancer Inst, 86, pp. 1766-1770.
18. Mileshkin, L and Biagi, J and Mitchell, P and Underhill, C and Grigg, A and Bell, R and (2003) Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: Adverse prognostic impact of advanced age Blood, 102, pp. 69-77.
19. Baz, R and Alemany, C and Green, R and Hussein, M. (2004) Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: A retrospective review Cancer, 101, pp. 790-795.
20. Pathak, R and Jayaraj, K and Blonde, L. (2003) Thalidomide-associated hyperglycemia and diabetes: Case report and review of literature Diabetes Care, 26, pp. 1322-1323.
21. Cavaletti, G and Beronio, A and Reni, L and Ghiglione, E and Schenone, A and Briani, C and (2004) Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study Neurology, 62, pp. 2291-2293.
22. Cherian, G and Thomas, D and Rule, S. (2006) The efficacy of low dose thalidomide in refractory/relapsed myeloma - a retrospective audit Leuk Lymphoma, 47(11), pp. 2409-2411.
23. Wechalekar, A and Chen, C and Sutton, D and Reece, D and Voralia, M and Stewart, A. (2003) Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma Leuk Lymphoma, 44, pp. 1147-1149.
24. Durie, B. (2002) Low-dose thalidomide in myeloma: Efficacy and biologic significance Semin Oncol, 29, pp. 34-38.
25. Kees, M and Dimou, G and Sillaber, C and Drach, J and Ackermann, J and Lechner, K and (2003) Low dose thalidomide in patients with relapsed or refractory multiple myeloma Leuk Lymphoma, 44, pp. 1943-1946.